



May 19, 2026

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

Symbol: LUPIN

BSE Limited

P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Scrip Code: Equity - 500257

Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

We are pleased to enclose a Press Release titled "Lupin Makes its Debut in Dow Jones Best-in-Class Indices 2026".

The same is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)**

Encl.: a/a.

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

info@lupin.com | www.lupin.com

Lupin Makes its Debut in Dow Jones Best-in-Class Indices 2026

Mumbai, May 19, 2026: Global pharma major Lupin Limited (Lupin) today announced that it has been featured for the first time in the **Dow Jones Best-in-Class (DJBIC)** Indices, underscoring the company's strong commitment to sustainable, responsible, and ethical business practices. Lupin has been listed in both the DJBIC World Index and the DJBIC Emerging Markets Index.

The DJBIC World Index ranks top-performing companies globally by strong ESG performance, while the DJBIC Emerging Markets Index highlights sustainability leaders across emerging economies. Lupin was previously ranked among the top 1% globally in the S&P Global Corporate Sustainability Assessment (CSA) 2025, achieving an industry-leading score of 91/100.

The Dow Jones Best-in-Class Indices recognize companies that demonstrate exceptional performance across key Environmental, Social, and Governance (ESG) parameters, based on leading S&P Global CSA scores. Inclusion in these prestigious indices reinforces Lupin's credibility with global investors, strengthens its competitive positioning, and places the company among a distinguished group of global leaders recognized for best-in-class sustainability performance.

"Lupin's inclusion in the Dow Jones Best-in-Class Indices reflects the strength of our governance framework and financial discipline and marks a meaningful advancement in our sustainability journey. This recognition reinforces our long-term value creation agenda—anchored in responsible growth, resilient performance, and our continued commitment to delivering affordable, high-quality medicines to patients worldwide," said **Ramesh Swaminathan, Executive Director, Global CFO, Head of IT and API Plus SBU, Lupin.**

Lupin remains committed to advancing its sustainability agenda through science-based targets, environmental stewardship, quality and safety standards, inclusive workplace practices, and responsible supply chain management, all driving towards creating long-term value for patients, communities, and stakeholders.

About Dow Jones Best-in-Class Indices

The Dow Jones Best-in-Class Indices (formerly DJSI) are float-adjusted market capitalization (FMC) weighted indices measuring the performance of companies selected from an Underlying Universe that satisfy specific criteria based on the S&P Global CSA Scores using a best-in-class approach.

Dow Jones Best-in-Class World: The Dow Jones Best-in-Class World Index tracks the performance of the top 10% of the 2,500 largest companies in the S&P Global Broad Market Index that lead the field in terms of sustainability.

Dow Jones Best-in-Class Emerging Markets: The Dow Jones Best-in-Class Emerging Markets Index tracks the performance of the top 10% of the 800 largest Emerging Markets companies in the S&P Global Broad Market Index that lead the field in terms of sustainability.

<https://www.spglobal.com/sustainable1/en/csa/invited-companies>

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To know more, visit www.lupin.com or follow us on LinkedIn <https://www.linkedin.com/company/lupin>

For further information or queries, please contact:

Rajalakshmi Azariah

Vice President & Global Head – Corporate Communications, Lupin

rajalakshmi.azariah@lupin.com